Literature DB >> 28003379

Key Residues at Third CDR3β Position Impact Structure and Antigen Recognition of Human Invariant NK TCRs.

Kenji Chamoto1, Tingxi Guo1,2, Stephen W Scally3, Yuki Kagoya1, Mark Anczurowski1,2, Chung-Hsi Wang1,2, Muhammed A Rahman1, Kayoko Saso1, Marcus O Butler1,2,4, Priscilla P L Chiu5,6, Jean-Philippe Julien2,3,7, Naoto Hirano8,2.   

Abstract

The human invariant NK (iNK) TCR is largely composed of the invariant TCR Vα24-Jα18 chain and semivariant TCR Vβ11 chains with variable CDR3β sequences. The direct role of CDR3β in Ag recognition has been studied extensively. Although it was noted that CDR3β can interact with CDR3α, how this interaction might indirectly influence Ag recognition is not fully elucidated. We observed that the third position of Vβ11 CDR3 can encode an Arg or Ser residue as a result of somatic rearrangement. Clonotypic analysis of the two iNK TCR types with a single amino acid substitution revealed that the staining intensity by anti-Vα24 Abs depends on whether Ser or Arg is encoded. When stained with an anti-Vα24-Jα18 Ab, human primary invariant NKT cells could be divided into Vα24 low- and high-intensity subsets, and Arg-encoding TCR Vβ11 chains were more frequently isolated from the Vα24 low-intensity subpopulation compared with the Vα24 high-intensity subpopulation. The Arg/Ser substitution also influenced Ag recognition as determined by CD1d multimer staining and CD1d-restricted functional responses. Importantly, in silico modeling validated that this Ser-to-Arg mutation could alter the structure of the CDR3β loop, as well as the CDR3α loop. Collectively, these results indicate that the Arg/Ser encoded at the third CDR3β residue can effectively modulate the overall structure of, and Ag recognition by, human iNK TCRs.
Copyright © 2017 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 28003379      PMCID: PMC5262525          DOI: 10.4049/jimmunol.1601556

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  47 in total

1.  A molecular basis for the exquisite CD1d-restricted antigen specificity and functional responses of natural killer T cells.

Authors:  Kwok S Wun; Garth Cameron; Onisha Patel; Siew Siew Pang; Daniel G Pellicci; Lucy C Sullivan; Santosh Keshipeddy; Mary H Young; Adam P Uldrich; Meena S Thakur; Stewart K Richardson; Amy R Howell; Petr A Illarionov; Andrew G Brooks; Gurdyal S Besra; James McCluskey; Laurent Gapin; Steven A Porcelli; Dale I Godfrey; Jamie Rossjohn
Journal:  Immunity       Date:  2011-03-03       Impact factor: 31.745

2.  Optimization of T-cell Reactivity by Exploiting TCR Chain Centricity for the Purpose of Safe and Effective Antitumor TCR Gene Therapy.

Authors:  Toshiki Ochi; Munehide Nakatsugawa; Kenji Chamoto; Shinya Tanaka; Yuki Yamashita; Tingxi Guo; Hiroshi Fujiwara; Masaki Yasukawa; Marcus O Butler; Naoto Hirano
Journal:  Cancer Immunol Res       Date:  2015-05-05       Impact factor: 11.151

3.  iNKT cell frequency in peripheral blood of Caucasian children and adolescent: the absolute iNKT cell count is stable from birth to adulthood.

Authors:  K Bienemann; K Iouannidou; K Schoenberg; F Krux; S Reuther; O Feyen; K Bienemann; F Schuster; M Uhrberg; H-J Laws; A Borkhardt
Journal:  Scand J Immunol       Date:  2011-10       Impact factor: 3.487

4.  Expression of two T cell receptor alpha chains: dual receptor T cells.

Authors:  E Padovan; G Casorati; P Dellabona; S Meyer; M Brockhaus; A Lanzavecchia
Journal:  Science       Date:  1993-10-15       Impact factor: 47.728

5.  A molecular basis for NKT cell recognition of CD1d-self-antigen.

Authors:  Thierry Mallevaey; Andrew J Clarke; James P Scott-Browne; Mary H Young; Laila C Roisman; Daniel G Pellicci; Onisha Patel; Julian P Vivian; Jennifer L Matsuda; James McCluskey; Dale I Godfrey; Philippa Marrack; Jamie Rossjohn; Laurent Gapin
Journal:  Immunity       Date:  2011-03-03       Impact factor: 31.745

6.  Specific roles of each TCR hemichain in generating functional chain-centric TCR.

Authors:  Munehide Nakatsugawa; Yuki Yamashita; Toshiki Ochi; Shinya Tanaka; Kenji Chamoto; Tingxi Guo; Marcus O Butler; Naoto Hirano
Journal:  J Immunol       Date:  2015-02-20       Impact factor: 5.422

7.  Differential recognition of CD1d-alpha-galactosyl ceramide by the V beta 8.2 and V beta 7 semi-invariant NKT T cell receptors.

Authors:  Daniel G Pellicci; Onisha Patel; Lars Kjer-Nielsen; Siew Siew Pang; Lucy C Sullivan; Konstantinos Kyparissoudis; Andrew G Brooks; Hugh H Reid; Stephanie Gras; Isabelle S Lucet; Ruide Koh; Mark J Smyth; Thierry Mallevaey; Jennifer L Matsuda; Laurent Gapin; James McCluskey; Dale I Godfrey; Jamie Rossjohn
Journal:  Immunity       Date:  2009-07-17       Impact factor: 31.745

8.  Innate-like control of human iNKT cell autoreactivity via the hypervariable CDR3beta loop.

Authors:  Gediminas Matulis; Joseph P Sanderson; Nikolai M Lissin; Maria B Asparuhova; Gopal R Bommineni; Daniel Schümperli; Richard R Schmidt; Peter M Villiger; Bent K Jakobsen; Stephan D Gadola
Journal:  PLoS Biol       Date:  2010-06-22       Impact factor: 8.029

Review 9.  Recognition of CD1d-restricted antigens by natural killer T cells.

Authors:  Jamie Rossjohn; Daniel G Pellicci; Onisha Patel; Laurent Gapin; Dale I Godfrey
Journal:  Nat Rev Immunol       Date:  2012-11-16       Impact factor: 53.106

10.  Recognition of β-linked self glycolipids mediated by natural killer T cell antigen receptors.

Authors:  Daniel G Pellicci; Andrew J Clarke; Onisha Patel; Thierry Mallevaey; Travis Beddoe; Jérôme Le Nours; Adam P Uldrich; James McCluskey; Gurdyal S Besra; Steven A Porcelli; Laurent Gapin; Dale I Godfrey; Jamie Rossjohn
Journal:  Nat Immunol       Date:  2011-07-31       Impact factor: 25.606

View more
  1 in total

1.  A Subset of Human Autoreactive CD1c-Restricted T Cells Preferentially Expresses TRBV4-1+ TCRs.

Authors:  Tingxi Guo; Ming Yin Koo; Yuki Kagoya; Mark Anczurowski; Chung-Hsi Wang; Kayoko Saso; Marcus O Butler; Naoto Hirano
Journal:  J Immunol       Date:  2017-12-13       Impact factor: 5.422

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.